Basilea launches Phase 3 study for antifungal drug to treat severe mold infections in adults.

Basilea Pharmaceutica has launched a Phase 3 study for its antifungal drug fosmanogepix to treat invasive mold infections in adults. The FORWARD-IM study aims to assess the drug's safety and effectiveness, focusing on immunocompromised patients who face high mortality rates from such infections. Expected to conclude in the first quarter of 2028, fosmanogepix has already received FDA Fast Track and Orphan Drug designations for several indications.